Drug tArgets, Target Identification, Validation and Screening

The Practice of Medicinal Chemistry

Volumn , Issue , 2008, Pages 106-121

  Zavitz, Kenton H ^a   Bartel, Paul L ^a   Hobden, Adrian N ^a  

^a Utah   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956304479     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374194-3.00005-6     Document Type: Chapter

References (63)

1. Cohen, S. N., Boyer, H. W. Process for producing biologically functional molecular chimeras. US Patent 4,237,224, 1980.
2. Reichert J.M. New biopharmaceuticals in the USA: trends in develop-ment and marketing approvals 1995-1999. Trends Biotechnol. 2000, 18(9):364-369.
3. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182.
4. Miller L.K. Insect baculoviruses: powerful gene expression vectors. Bioessays 1989, 11(4):91-95.
5. Liljestrom P., Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (NY) 1991, 9(12):1356-1361.
6. Baum E.Z., Bebernitz G.A., Gluzman Y. Isolation of mutants of human immunodeficiency virus protease based on the toxicity of the enzyme in Escherichia coli. Proc. Natl. Acad. Sci. USA 1990, 87(14):5573-5577.
7. Wei M.Q., Metharom P., Ellem K.A., Barth S. Search for "weapons of mass destruction" for cancer - immuno/gene therapy comes of age. Cell Mol. Immunol. 2005, 2(5):351-357.
8. Hawkes C.A., McLaurin J. Immunotherapy as treatment for Alzheimer's disease. Expert Rev. Neurother. 2007, 7(11):1535-1548.
9. Senior K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol. 2002, 1(1):3.
10. Gamba G. Molecular physiology and pathophysiology of electroneutral cation-chloride cotransporters. Physiol. Rev. 2005, 85(2):423-493.
11. Lemere C.A., Lopera F., Kosik K.S., Lendon C.L., Ossa J., Saido T.C., Yamaguchi H., Ruiz A., Martinez A., Madrigal L., Hincapie L., Arango J.C., Anthony D.C., Koo E.H., Goate A.M., Selkoe D.J. The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat. Med. 1996, 2(10):1146-1150.
12. Mullan M., Crawford F., Axelman K., Houlden H., Lilius L., Winblad B., Lannfelt L. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat. Genet. 1992, 1(5):345-347.
13. Murrell J., Farlow M., Ghetti B., Benson M.D. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 1991, 254(5028):97-99.
14. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 1996, 2(8):864-870.
15. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297(5580):353-356.
16. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298(5600):1912-1934.
17. Matsuo R., Ochiai W., Nakashima K., Taga T. A new expression cloning strategy for isolation of substrate-specific kinases by using phosphorylation site-specific antibody. J. Immunol. Meth. 2001, 247(1-2):141-151.
18. Lock P., Abram C.L., Gibson T., Courtneidge S.A. A new method for isolating tyrosine kinase substrates used to identify fish, an SH3 and PX domain-containing protein, and Src substrate. EMBO J. 1998, 17(15):4346-4357.
19. Fields S., Song O. A novel genetic system to detect protein-protein interactions. Nature 1989, 340(6230):245-246.
20. Bartel, P. L. Fields S., The Yeast Two-Hybrid System. Oxford University Press: New York, 1997.
21. Vidal M., Endoh H. Prospects for drug screening using the reverse two-hybrid system. Trends Biotechnol. 1999, 17(9):374-381.
22. Young K., Lin S., Sun L., Lee E., Modi M., Hellings S., Husbands M., Ozenberger B., Franco R. Identification of a calcium channel modulator using a high throughput yeast two-hybrid screen. Nat. Biotechnol. 1998, 16(10):946-950.
23. Iorns E., Lord C.J., Turner N., Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat. Rev. Drug Discov. 2007, 6(7):556-568.
24. Brass A.L., Dykxhoorn D.M., Benita Y., Yan N., Engelman A., Xavier R.J., Lieberman J., Elledge S.J. Identification of host proteins required for HIV infection through a functional genomic screen. Science 2008.
25. Pan Q., Bao L.W., Kleer C.G., Sabel M.S., Griffith K.A., Teknos T.N., Merajver S.D. Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res. 2005, 65(18):8366-8371.
26. Singer O., Marr R.A., Rockenstein E., Crews L., Coufal N.G., Gage F.H., Verma I.M., Masliah E. Targeting BACE1 with siRNAs ameliorates Alzheimer's disease neuropathology in a transgenic model. Nat. Neurosci. 2005, 8(10):1343-1349.
27. Boehm J.S., Zhao J.J., Yao J., Kim S.Y., Firestein R., Dunn I.F., Sjostrom S.K., Garraway L.A., Weremowicz S., Richardson A.L., Greulich H., Stewart C.J., Mulvey L.A., Shen R.R., Ambrogio L., Hirozane-Kishikawa T., Hill D.E., Vidal M., Meyerson M., Grenier J.K., Hinkle G., Root D.E., Roberts T.M., Lander E.S., Polyak K., Hahn W.C. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007, 129(6):1065-1079.
28. de Fougerolles A., Vornlocher H.P., Maraganore J., Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 2007, 6(6):443-453.
29. Napoli C., Lemieux C., Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 1990, 2(4):279-289.
30. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391(6669):806-811.
31. Tuschl T., Zamore P.D., Lehmann R., Bartel D.P., Sharp P.A. Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev. 1999, 13(24):3191-3197.
32. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411(6836):494-498.
33. Paddison P.J., Caudy A.A., Bernstein E., Hannon G.J., Conklin D.S. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 2002, 16(8):948-958.
34. Yang D., Buchholz F., Huang Z., Goga A., Chen C.Y., Brodsky F.M., Bishop J.M. Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate effective RNA interference in mammalian cells. Proc. Natl. Acad. Sci. USA 2002, 99(15):9942-9947.
35. Kittler R., Surendranath V., Heninger A.K., Slabicki M., Theis M., Putz G., Franke K., Caldarelli A., Grabner H., Kozak K., Wagner J., Rees E., Korn B., Frenzel C., Sachse C., Sonnichsen B., Guo J., Schelter J., Burchard J., Linsley P.S., Jackson A.L., Habermann B., Buchholz F. Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies. Nat. Meth. 2007, 4(4):337-344.
36. Garrus J.E., von Schwedler U.K., Pornillos O.W., Morham S.G., Zavitz K.H., Wang H.E., Wettstein D.A., Stray K.M., Cote M., Rich R.L., Myszka D.G., Sundquist W.I. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 2001, 107(1):55-65.
37. Paddison P.J., Silva J.M., Conklin D.S., Schlabach M., Li M., Aruleba S., Balija V., O'Shaughnessy A., Gnoj L., Scobie K., Chang K., Westbrook T., Cleary M., Sachidanandam R., McCombie W.R., Elledge S.J., Hannon G.J. A resource for large-scale RNA-interference-based screens in mammals. Nature 2004, 428(6981):427-431.
38. Popov N., Wanzel M., Madiredjo M., Zhang D., Beijersbergen R., Bernards R., Moll R., Elledge S.J., Eilers M. The ubiquitin-specific protease USP28 is required for MYC stability. Nat. Cell Biol. 2007, 9(7):765-774.
39. Ngo V.N., Davis R.E., Lamy L., Yu X., Zhao H., Lenz G., Lam L.T., Dave S., Yang L., Powell J., Staudt L.M. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006, 441(7089):106-110.
40. MacKeigan J.P., Murphy L.O., Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat. Cell Biol. 2005, 7(6):591-600.
41. Kittler R., Buchholz F. Functional genomic analysis of cell division by endoribonuclease-prepared siRNAs. Cell Cycle 2005, 4(4):564-567.
42. Zhu C., Zhao J., Bibikova M., Leverson J.D., Bossy-Wetzel E., Fan J.B., Abraham R.T., Jiang W. Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference. Mol. Biol. Cell 2005, 16(7):3187-3199.
43. Hemann M.T., Fridman J.S., Zilfou J.T., Hernando E., Paddison P.J., Cordon-Cardo C., Hannon G.J., Lowe S.W. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat. Genet. 2003, 33(3):396-400.
44. Knight Z.A., Shokat K.M. Chemical genetics: where genetics and pharmacology meet. Cell 2007, 128(3):425-430.
45. Metzger D., White J.H., Chambon P. The human oestrogen receptor functions in yeast. Nature 1988, 334(6177):31-36.
46. Schena M., Yamamoto K.R. Mammalian glucocorticoid receptor derivatives enhance transcription in yeast. Science 1988, 241(4868):965-967.
47. Purvis I.J., Chotai D., Dykes C.W., Lubahn D.B., French F.S., Wilson E.M., Hobden A.N. An androgen-inducible expression system for Saccharomyces cerevisiae. Gene 1991, 106(1):35-42.
48. McHale M.M., Cieslinski L.B., Eng W.K., Johnson R.K., Torphy T.J., Livi G.P. Expression of human recombinant cAMP phosphodiesterase isozyme IV reverses growth arrest phenotypes in phosphodiesterase-deficient yeast. Mol. Pharmacol. 1991, 39(2):109-113.
49. Konopka J.B., Fields S. The pheromone signal pathway in Saccharomyces cerevisiae. Antonie Van Leeuwenhoek 1992, 62(1-2):95-108.
50. King K., Dohlman H.G., Thorner J., Caron M.G., Lefkowitz R.J. Control of yeast mating signal transduction by a mammalian beta 2-adrenergic receptor and Gs alpha subunit. Science 1990, 250(4977):121-123.
51. Klein C., Paul J.I., Sauve K., Schmidt M.M., Arcangeli L., Ransom J., Trueheart J., Manfredi J.P., Broach J.R., Murphy A.J. Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast. Nat. Biotechnol. 1998, 16(13):1334-1337.
52. Potenza M.N., Lerner M.R. A rapid quantitative bioassay for evaluating the effects of ligands upon receptors that modulate cAMP levels in a melanophore cell line. Pigment Cell Res. 1992, 5(6):372-378.
53. Carrithers M.D., Marotti L.A., Yoshimura A., Lerner M.R. A melanophore-based screening assay for erythropoietin receptors. J. Biomol. Screen. 1999, 4(1):9-14.
54. Humes H.D. Insights into ototoxicity. Analogies to nephrotoxicity. Ann NYAcad. Sci. 1999, 884:15-18.
55. Delpire E., Lu J., England R., Dull C., Thorne T. Deafness and imbalance associated with inactivation of the secretory Na-K-2Cl co-transporter. Nat. Genet. 1999, 22(2):192-195.
56. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39(3):409-421.
57. Eriksen J.L., Sagi S.A., Smith T.E., Weggen S., Das P., McLendon D.C., Ozols V.V., Jessing K.W., Zavitz K.H., Koo E.H., Golde T.E. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest. 2003, 112(3):440-449.
58. Kukar T., Prescott S., Eriksen J.L., Holloway V., Murphy M.P., Koo E.H., Golde T.E., Nicolle M.M. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci. 2007, 8:54.
59. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408(6815):982-985.
60. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400(6740):173-177.
61. Nebert D.W. Proposed role of drug-metabolizing enzymes: regulation of steady state levels of the ligands that effect growth, homeostasis, differentiation, and neuroendocrine functions. Mol. Endocrinol. 1991, 5(9):1203-1214.
62. Myhr B.C. Validation studies with Muta Mouse: a transgenic mouse model for detecting mutations in vivo. Environ. Mol. Mutagen. 1991, 18(4):308-315.
63. Shephard S.E., Sengstag C., Lutz W.K., Schlatter C. Mutations in liver DNA of lacI transgenic mice (Big Blue) following subchronic exposure to 2-acetylaminofluorene. Mutat. Res. 1993, 302(2):91-96.